OrthoPediatrics Corp. (NASDAQ:KIDS – Get Rating) has received a consensus recommendation of “Buy” from the eight analysts that are covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $55.33.
A number of analysts have issued reports on KIDS shares. Truist Financial lifted their target price on shares of OrthoPediatrics from $53.00 to $57.00 and gave the company a “buy” rating in a research note on Monday, April 17th. Needham & Company LLC reaffirmed a “buy” rating and set a $51.00 target price on shares of OrthoPediatrics in a research report on Monday, April 17th. TheStreet lowered shares of OrthoPediatrics from a “c” rating to a “d+” rating in a report on Wednesday, March 1st. Finally, 1-800-FLOWERS.COM reaffirmed a “maintains” rating on shares of OrthoPediatrics in a report on Tuesday, May 2nd.
Insider Activity at OrthoPediatrics
In related news, General Counsel Daniel J. Gerritzen sold 3,315 shares of the stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $44.62, for a total value of $147,915.30. Following the sale, the general counsel now directly owns 35,527 shares in the company, valued at approximately $1,585,214.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Mark C. Throdahl sold 4,515 shares of the firm’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $43.83, for a total value of $197,892.45. Following the completion of the transaction, the director now directly owns 128,024 shares of the company’s stock, valued at $5,611,291.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Daniel J. Gerritzen sold 3,315 shares of the firm’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $44.62, for a total transaction of $147,915.30. Following the completion of the transaction, the general counsel now directly owns 35,527 shares of the company’s stock, valued at $1,585,214.74. The disclosure for this sale can be found here. Insiders have sold 26,761 shares of company stock worth $1,208,081 in the last ninety days. Company insiders own 29.50% of the company’s stock.
Institutional Investors Weigh In On OrthoPediatrics
OrthoPediatrics Price Performance
OrthoPediatrics stock opened at $45.19 on Monday. The firm’s 50 day simple moving average is $45.45 and its 200-day simple moving average is $43.76. The company has a market cap of $1.05 billion, a P/E ratio of 225.95 and a beta of 0.89. OrthoPediatrics has a fifty-two week low of $35.67 and a fifty-two week high of $60.75.
OrthoPediatrics (NASDAQ:KIDS – Get Rating) last released its earnings results on Tuesday, February 28th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.10). The firm had revenue of $30.99 million during the quarter, compared to analysts’ expectations of $31.01 million. OrthoPediatrics had a negative return on equity of 5.32% and a net margin of 2.72%. On average, analysts expect that OrthoPediatrics will post -0.94 EPS for the current fiscal year.
OrthoPediatrics Company Profile
OrthoPediatrics Corp. is an orthopedic company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. It offers products relating to trauma and deformity, scoliosis, and sports medicine and other procedures. The company was founded by Erin Springer Yount and Nick A.
- Get a free copy of the StockNews.com research report on OrthoPediatrics (KIDS)
- MarketBeat Week in Review – 5/8 – 5/12
- An Updraft Is Brewing For DraftKings
- PepsiCo Hits “Sweet Spot” For APAC Growth, Macros Agree
- High-Risk Mullen Automotive Continues To Build Momentum
- 3 Recession-Proof Stocks With Nice Dividends
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.